E-LIB Suche - Ergebnisse für: Felizarta, Franco

1

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/..:

Schneider, Stefan ; Blick, Gary ; Burke, Christina...
Infectious Diseases and Therapy. 13 (2024) 4 - p. 891-906 , 2024

Link: https://doi.org/10.1007/..

2

Durability of sustained virological response to glecaprevir..:

Poordad, Fred ; Felizarta, Franco ; Yao, Betty B....
Liver International. 42 (2022) 6 - p. 1278-1286 , 2022

Link: https://doi.org/10.1111/..

3

Phase IIa Proof-of-Concept Evaluation of the Antiviral Effi..:

Spinner, Christoph D ; Felizarta, Franco ; Rizzardini, Giuliano...
Clinical Infectious Diseases. 75 (2022) 5 - p. 786-794 , 2022

Link: https://doi.org/10.1093/..

4

Long‐term safety and efficacy results in hepatitis C virus ..:

Poordad, Fred ; Castro, RuiSarmento E. ; Asatryan, Armen...
Journal of Viral Hepatitis. 27 (2020) 5 - p. 497-504 , 2020

Link: https://doi.org/10.1111/..

5

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve pat..:

Brown Jr, Robert S. ; Buti, Maria ; Rodrigues, Lino...
Journal of Hepatology. 72 (2020) 3 - p. 441-449 , 2020

Link: https://doi.org/10.1016/..

6

Safety and efficacy of glecaprevir/pibrentasvir in patients..:

Grebely, Jason ; Dore, Gregory J. ; Alami, Negar N....
International Journal of Drug Policy. 66 (2019) - p. 73-79 , 2019

Link: https://doi.org/10.1016/..

7

SAT-255-Long-term safety and efficacy results in hepatitis ..:

Poordad, Fred ; Castro, Rui Sarmento E. ; Asatryan, Armen...
Journal of Hepatology. 70 (2019) 1 - p. e745-e746 , 2019

Link: https://doi.org/10.1016/..

8

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and ..:

DeJesus, Edwin ; Harward, Sara ; Jewell, Roxanne C...
Clinical Infectious Diseases. 71 (2019) 5 - p. 1255-1262 , 2019

Link: https://doi.org/10.1093/..

9

Pharmacokinetics and antiviral activity of cabotegravir and..:

Patel, Parul ; D'Amico, Ronald ; Crauwels, Herta...
Journal of Antimicrobial Chemotherapy. 75 (2019) 3 - p. 648-655 , 2019

Link: https://doi.org/10.1093/..

10

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 p..:

Wyles, David ; Poordad, Fred ; Wang, Stanley...
Hepatology. 67 (2018) 2 - p. 514-523 , 2018

Link: https://doi.org/10.1002/..

11

Glecaprevir/Pibrentasvir in patients with hepatitis C virus..:

Poordad, Fred ; Pol, Stanislas ; Asatryan, Armen...
Hepatology. 67 (2018) 4 - p. 1253-1260 , 2018

Link: https://doi.org/10.1002/..

12

MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or ..:

Poordad, Fred ; Pol, Stanislas ; Asatryan, Armen...
Gastroenterology. 152 (2017) 5 - p. S1057 , 2017

Link: https://doi.org/10.1016/..

13

EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasv..:

Forns, Xavier ; Lee, Sam ; Valdes, Joaquin M....
Gastroenterology. 152 (2017) 5 - p. S1061 , 2017

Link: https://doi.org/10.1016/..

14

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C v..:

Poordad, Fred ; Felizarta, Franco ; Asatryan, Armen...
Hepatology. 66 (2017) 2 - p. 389-397 , 2017

Link: https://doi.org/10.1002/..

15

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12..:

Poordad, Fred ; Pol, Stanislas ; Asatryan, Armen...
Journal of Virus Eradication. 3 (2017) - p. 28-29 , 2017

Link: https://doi.org/10.1016/..